Cryosite Ltd
ASX:CTE
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| AU |
|
Cryosite Ltd
ASX:CTE
|
58.3m AUD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
189.6B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
149.1B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
46.3T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
35.6B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
292.3B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
35.6B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
28.4B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27.9B USD |
Loading...
|
|
| CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
163.2B HKD |
Loading...
|
Market Distribution
| Min | -6 907 100% |
| 30th Percentile | 21.6% |
| Median | 38.3% |
| 70th Percentile | 58.2% |
| Max | 2 095.9% |
Other Profitability Ratios
Cryosite Ltd
Glance View
Cryosite Ltd. engages in the provision of long term storage, supply chain logistics management of pharmaceutical products used in clinical trials and biological materials. The company is headquartered in Sydney, New South Wales. The company went IPO on 2002-05-09. The firm operates through two segments, which include Clinical Trials and Biological Services Logistics, and Cord Blood and Tissue Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns and biological services to the clinical trial and research industry. The Cord Blood and Tissue Storage segment provides long-term storage for cord blood and tissue samples. The firm engages in clinical trial supply chain from importation, receipt, specialized ambient, cold, frozen, and liquid nitrogen storage for temperature-sensitive products, distribution, and reverse logistics management.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Cryosite Ltd is 63%, which is above its 3-year median of 62.4%.
Over the last 3 years, Cryosite Ltd’s Gross Margin has increased from 58.2% to 63%. During this period, it reached a low of 58.2% on Jun 30, 2022 and a high of 64.5% on Jan 1, 2025.
